Posted by Michael Wonder on 28 May 2026
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer
28 May 2026 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG naïve, high-risk non-muscle invasive bladder cancer.
Efficacy was evaluated in the POTOMAC study, a randomised, open-label, multi-centre trial that enrolled 1,018 patients with high-risk non-muscle invasive bladder cancer following transurethral resection of bladder tumour.
